Roche lines up at the FDA's 10-yard line with $1.7B Ignyta buyout
Cancer drug powerhouse Roche $RHHBY has swooped in to buy Ignyta $RXDX for $1.7 billion, putting the pharma giant in direct competition with Loxo Oncology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
